Ping Guan

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• STCM-YOLO: a small object detection algorithm for unmanned aerial vehicle images based on the improved Swin Transformer and the fusion attention mechanism

  Journal of Electronic Imaging · 2025-11-25

• Cenozoic sandstone provenance in the Qaidam Basin of China, and its implications for the deformation history of the Tibetan Plateau

  Palaeogeography Palaeoclimatology Palaeoecology · 2025-07-05

• Abstract CT227: Quantum mechanics-based multi-tensor AI/ML discovery of a whole-transcriptome predictor of response and survival in patients treated with dabrafenib and trametinib in the tumor-agnostic small-cohort NCI-MATCH subprotocol H with validation in three tumor types in TCGA

  Cancer Research · 2025-04-25 · 1 citations

• Comprehensive Molecular and Genomic Analysis of NCI-MATCH Subprotocol Y: Capivasertib in Patients With an <i>AKT1 E17K</i> –Mutated Tumor

  JCO Precision Oncology · 2025-03-01 · 1 citations

• Supplementary Table S4 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D

  2025-02-17

• Supplementary Figure S3 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1DPreprint

  2025-02-17

• Supplementary Figure S7 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1DPreprint

  2025-02-17

• Supplementary Figure S4 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1DPreprint

  2025-02-17

• Supplementary Table S2 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D

  2025-02-17

• Supplementary Figure S7 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1DPreprint

  2025-02-17

• Supplementary Table S5 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D

  2025-02-17

• Supplementary Figure S6 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1DPreprint

  2025-02-17

• Supplementary Table S1 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D

  2025-02-17

• Supplementary Table S6 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D

  2025-02-17

• Supplementary Figure S2 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1DPreprint

  2025-02-17

• Supplementary Table S3 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D

  2025-02-17

• Data from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1DPreprint

  2025-02-17

• Supplementary Table S8 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D

  2025-02-17

• Supplementary Figure S1 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1DPreprint

  2025-02-17

• Supplementary Figure S5 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1DPreprint

  2025-02-17